Mineralocorticoid receptor antagonists

US8933113B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Alejandro Crespo · Edison, US
• Ping Lan · Plainsboro, US
• Rudrajit Mal · Edison, US
• Anthony Ogawa · New Providence, US
• Hong Shen · Shanghai, CN
• Peter J. Sinclair · Highland Park, US
• Zhongxiang Sun · Princeton, US
• Ellen K. Vande Bunte · Hawthorne, US
• Zhicai Wu · Montvale, US
• Kun Liu · Edison, US
• Robert J. DeVita · Westfield, US
• Dong-Ming Shen · Edison, US
• Min Shu · Green Brook, US
• John Qiang Tan · New Brunswick, US
• Changhe Qi · Shanghai, CN
• Yuguang Wang · Shanghai, CN
• Richard Thomas Beresis · Shanghai, CN

Key dates

• Filing date: Jan 19, 2012
• Grant date: Jan 13, 2015
• Expiry date: Jan 19, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too.